Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:George_Goldsmith
|
| gptkbp:clinical_trials |
psilocybin for depression
|
| gptkbp:country |
gptkb:United_Kingdom
|
| gptkbp:focusesOn |
psilocybin therapy
treatment-resistant depression |
| gptkbp:founded |
2016
|
| gptkbp:founder |
gptkb:Ekaterina_Malievskaia
gptkb:George_Goldsmith |
| gptkbp:headquarters_location |
gptkb:London,_United_Kingdom
|
| https://www.w3.org/2000/01/rdf-schema#label |
COMPASS Pathways
|
| gptkbp:industry |
mental health care
|
| gptkbp:IPODate |
September 2020
|
| gptkbp:listedOn |
gptkb:NASDAQ
|
| gptkbp:mission |
accelerate patient access to evidence-based innovation in mental health
|
| gptkbp:notableProduct |
gptkb:COMP360_(psilocybin_therapy)
|
| gptkbp:publiclyTraded |
yes
|
| gptkbp:servesArea |
global
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
gptkb:CMPS
|
| gptkbp:website |
https://compasspathways.com/
|
| gptkbp:bfsParent |
gptkb:Ekaterina_Malievskaia
|
| gptkbp:bfsLayer |
6
|